Last updated: June 29, 2026
McNeil-PPC v. Perrigo (1:05-cv-01321): Litigation Summary, Patent Issues, and Generic Entry Risk Analysis
McNeil-PPC, Inc. sued Perrigo Company in 2005 in case 1:05-cv-01321 over intellectual property covering a marketed McNeil product and related generic entry activity. The docket record required to produce a complete litigation summary tied to the asserted patents, claim scope, procedural posture (PTO reexams, motions, claim construction), and any settlement or court rulings is not available in the provided input. Without those specifics, a complete and accurate patent-by-patent, timeline-level analysis cannot be generated.
What patents were asserted in McNeil-PPC, Inc. v. Perrigo Company (1:05-cv-01321)?
No asserted patent numbers, expiration dates, or claims-at-issue are provided in the input. A valid litigation analysis depends on the exact patent list and the asserted infringement theory (formulation, composition, method of use, or manufacturing). Those identifiers are not included.
How do you determine which IP claims drove the dispute?
A correct answer requires, at minimum, the complaint’s “patent(s) in suit” section and the claim chart positions reflected in:
- the complaint (infringement allegations),
- any amended pleadings,
- Markman/claim construction orders (if issued),
- summary judgment orders (if issued),
- final judgments or dismissals.
No such docket or order text is included.
When did this litigation begin and what was the procedural timeline (motions, hearings, stays)?
The filing identifier 1:05-cv-01321 is provided, but the following timeline elements are missing:
- complaint filing date,
- answer date,
- motion to dismiss status,
- preliminary injunction posture (if any),
- Markman schedule and rulings,
- discovery milestones,
- summary judgment and trial dates,
- any stay due to related actions or PTO proceedings.
A timeline-level analysis cannot be completed without those dates from the docket.
What did the court decide in McNeil-PPC v. Perrigo (1:05-cv-01321)?
The decision text, disposition type, and outcome are not provided:
- dismissal for procedural defect,
- consent judgment,
- summary judgment of non-infringement or invalidity,
- finding of infringement,
- permanent injunction,
- dismissal with prejudice after settlement,
- or voluntary dismissal.
Without the final disposition, infringement/validity strength and generic-entry impact cannot be stated reliably.
Was there a Paragraph IV or Hatch-Waxman-type challenge connected to Perrigo’s ANDA?
The prompt identifies a party-versus-party IP case but does not include:
- the asserted Orange Book listings,
- the NDA/ANDA numbers,
- whether Perrigo filed an ANDA with a Paragraph IV certification,
- the triggering act (74x/ANDA notice),
- or any FDA approval and launch timeline.
A Hatch-Waxman analysis requires the drug product and certification context, which is not present.
What is the Orange Book status of the drug at issue in McNeil-PPC v. Perrigo?
Orange Book listings and patent types (drug substance, drug product, or method-of-use) are not provided. Without:
- the NDA number,
- the Orange Book patent list,
- and which of those patents were litigated,
an Orange Book status summary would be incomplete.
How strong was McNeil’s patent estate in this case (infringement vs validity)?
A strength assessment requires:
- the specific patents in suit,
- their prosecution history status (file wrapper elements),
- claim construction results,
- invalidity contentions (anticipation/obviousness/indefiniteness),
- and the court’s rulings.
No patent or ruling data is included.
How do you assess generic entry risk for Perrigo after (or during) 1:05-cv-01321?
Generic entry risk hinges on:
- whether the case ended with an enforceable injunction or a no-infringement/non-infringement ruling,
- whether any settlement included a launch date and/or terms barring design-arounds,
- and whether the FDA approval was blocked or permitted.
Settlement or injunction terms are not provided.
Did any settlement agreement resolve the dispute, and what were the terms?
Settlement terms are typically reflected in:
- docket entries (dismissal after settlement),
- court orders,
- sealed/unsealed stipulations,
- or public filings tying to ANDA exclusivity or launch restrictions.
No settlement entry or order text is included.
What formulation, manufacturing, or method-of-use issues were contested?
A technical analysis requires:
- asserted independent claim(s),
- the accused product specification,
- comparisons against McNeil’s claimed composition/process,
- and any expert report findings adopted by the court.
None of these details are included.
How does this case compare with other McNeil-PPC vs Perrigo patent litigations?
A comparative analysis requires a dataset of:
- other case numbers,
- overlapping patents and similar claim themes,
- outcomes and any appellate history.
No comparable cases are provided.
Key Takeaways
- Case identifier: McNeil-PPC, Inc. v. Perrigo Company, 1:05-cv-01321 is specified, but the input does not include the patent list, asserted claims, docket dates, court rulings, or settlement/injunction terms required for an accurate litigation summary.
- A patent estate and generic entry risk analysis cannot be completed without the complaint’s “patents in suit,” the operative procedural history, and the dispositive orders.
FAQs
- What information in the complaint determines which patents were litigated in 1:05-cv-01321?
- Which docket events typically signal a settlement in Hatch-Waxman patent cases like this one?
- How do claim construction rulings change the infringement/validity analysis in ANDA patent disputes?
- What court outcomes most strongly affect “design-around” opportunities for a generic challenger?
- How do Orange Book patent categories (drug substance, drug product, method-of-use) affect litigation scope?
References (APA)
- Case docket identifier provided in prompt: McNeil-PPC, Inc. v. Perrigo Company, 1:05-cv-01321.
